John Banks

TL;DR: Recommendations and recommendations on what samples should be used to detect pulmonary non-tuberculous mycobacterial infection and how to define lung disease attributable to NTM infection are presented.

TL;DR: The full guideline for the management of non-tuberculous mycobacterial pulmonary disease is published in Thorax and a summary of the recommendations and good practice points is provided.

TL;DR: A trial to compare clarithromycin and ciprofloxacin as third drugs added after 2 years of treatment with R and E for pulmonary disease caused by M avium-intracellulare, M malmoense and M xenopi found no differences in outcome between the REClari and RECipro groups.

TL;DR: Since the prognosis with drug treatment alone is so unpredictable it is suggested that resection might be part of first line treatment, and that it should usually be performed if patients fail to respond to initial chemotherapy or if they relapse.

TL;DR: Rifampicin and ethambutol given for a mean period of 15 months appeared to be a non-toxic, effective combination in patients with pulmonary infection caused by Mycobacterium kansasii.